CDK12 and neoplasm: We next obtained the cell lysates from the xenografted tumours, and to perform Western blotting analysis, the data showed that SR‐4835 administration resulted in a remarkable decrease in phosphorylation of RNA Pol II CTD at S2 instead of S5 (Figure S3E), indicative of the in vivo anti‐CDK12 power of SR‐4835.